273 related articles for article (PubMed ID: 27835903)
1. Tumor-targeting Salmonella typhimurium A1-R combined with temozolomide regresses malignant melanoma with a BRAF-V600E mutation in a patient-derived orthotopic xenograft (PDOX) model.
Kawaguchi K; Igarashi K; Murakami T; Chmielowski B; Kiyuna T; Zhao M; Zhang Y; Singh A; Unno M; Nelson SD; Russell TA; Dry SM; Li Y; Eilber FC; Hoffman RM
Oncotarget; 2016 Dec; 7(52):85929-85936. PubMed ID: 27835903
[TBL] [Abstract][Full Text] [Related]
2. Salmonella typhimurium A1-R targeting of a chemotherapy-resistant BRAF-V600E melanoma in a patient-derived orthotopic xenograft (PDOX) model is enhanced in combination with either vemurafenib or temozolomide.
Kawaguchi K; Igarashi K; Murakami T; Kiyuna T; Zhao M; Zhang Y; Nelson SD; Russell TA; Dry SM; Singh AS; Chmielowski B; Li Y; Unno M; Eilber FC; Hoffman RM
Cell Cycle; 2017 Jul; 16(13):1288-1294. PubMed ID: 28622068
[TBL] [Abstract][Full Text] [Related]
3. Tumor-Targeting Salmonella typhimurium A1-R Sensitizes Melanoma With a BRAF-V600E Mutation to Vemurafenib in a Patient-Derived Orthotopic Xenograft (PDOX) Nude Mouse Model.
Kawaguchi K; Igarashi K; Murakami T; Zhao M; Zhang Y; Chmielowski B; Kiyuna T; Nelson SD; Russell TA; Dry SM; Li Y; Unno M; Eilber FC; Hoffman RM
J Cell Biochem; 2017 Aug; 118(8):2314-2319. PubMed ID: 28106277
[TBL] [Abstract][Full Text] [Related]
4. Combination therapy of tumor-targeting Salmonella typhimurium A1-R and oral recombinant methioninase regresses a BRAF-V600E-negative melanoma.
Kawaguchi K; Higuchi T; Li S; Han Q; Tan Y; Igarashi K; Zhao M; Miyake K; Kiyuna T; Miyake M; Ohshiro H; Sugisawa N; Zhang Z; Razmjooei S; Wangsiricharoen S; Chmielowski B; Nelson SD; Russell TA; Dry SM; Li Y; Eckardt MA; Singh AS; Singh SR; Eilber FC; Unno M; Hoffman RM
Biochem Biophys Res Commun; 2018 Sep; 503(4):3086-3092. PubMed ID: 30166061
[TBL] [Abstract][Full Text] [Related]
5. Vemurafenib-resistant BRAF-V600E-mutated melanoma is regressed by MEK-targeting drug trametinib, but not cobimetinib in a patient-derived orthotopic xenograft (PDOX) mouse model.
Kawaguchi K; Murakami T; Chmielowski B; Igarashi K; Kiyuna T; Unno M; Nelson SD; Russell TA; Dry SM; Li Y; Eilber FC; Hoffman RM
Oncotarget; 2016 Nov; 7(44):71737-71743. PubMed ID: 27690220
[TBL] [Abstract][Full Text] [Related]
6. Tumor-targeting Salmonella typhimurium A1-R overcomes partial carboplatinum-resistance of a cancer of unknown primary (CUP).
Miyake K; Kiyuna T; Miyake M; Zhao M; Wangsiricharoen S; Kawaguchi K; Zhang Z; Higuchi T; Razmjooei S; Li Y; Nelson SD; Russell T; Singh A; Murakami T; Hiroshima Y; Momiyama M; Matsuyama R; Chishima T; Singh SR; Chawla SP; Eilber FC; Endo I; Hoffman RM
Tissue Cell; 2018 Oct; 54():144-149. PubMed ID: 30309504
[TBL] [Abstract][Full Text] [Related]
7. Tumor-targeting Salmonella typhimurium A1-R combined with recombinant methioninase and cisplatinum eradicates an osteosarcoma cisplatinum-resistant lung metastasis in a patient-derived orthotopic xenograft (PDOX) mouse model: decoy, trap and kill chemotherapy moves toward the clinic.
Igarashi K; Kawaguchi K; Kiyuna T; Miyake K; Miyake M; Li S; Han Q; Tan Y; Zhao M; Li Y; Nelson SD; Dry SM; Singh AS; Elliott IA; Russell TA; Eckardt MA; Yamamoto N; Hayashi K; Kimura H; Miwa S; Tsuchiya H; Eilber FC; Hoffman RM
Cell Cycle; 2018; 17(6):801-809. PubMed ID: 29374999
[TBL] [Abstract][Full Text] [Related]
8. Tumor-targeting Salmonella typhimurium A1-R in combination with doxorubicin eradicate soft tissue sarcoma in a patient-derived orthotopic xenograft (PDOX) model.
Murakami T; DeLong J; Eilber FC; Zhao M; Zhang Y; Zhang N; Singh A; Russell T; Deng S; Reynoso J; Quan C; Hiroshima Y; Matsuyama R; Chishima T; Tanaka K; Bouvet M; Chawla S; Endo I; Hoffman RM
Oncotarget; 2016 Mar; 7(11):12783-90. PubMed ID: 26859573
[TBL] [Abstract][Full Text] [Related]
9. Tumor targeting Salmonella typhimurium A1-R in combination with gemcitabine (GEM) regresses partially GEM-resistant pancreatic cancer patient-derived orthotopic xenograft (PDOX) nude mouse models.
Kawaguchi K; Miyake K; Zhao M; Kiyuna T; Igarashi K; Miyake M; Higuchi T; Oshiro H; Bouvet M; Unno M; Hoffman RM
Cell Cycle; 2018; 17(16):2019-2026. PubMed ID: 29963961
[TBL] [Abstract][Full Text] [Related]
10. Combining Tumor-Selective Bacterial Therapy with Salmonella typhimurium A1-R and Cancer Metabolism Targeting with Oral Recombinant Methioninase Regressed an Ewing's Sarcoma in a Patient-Derived Orthotopic Xenograft Model.
Miyake K; Kiyuna T; Li S; Han Q; Tan Y; Zhao M; Oshiro H; Kawaguchi K; Higuchi T; Zhang Z; Razmjooei S; Barangi M; Wangsiricharoen S; Murakami T; Singh AS; Li Y; Nelson SD; Eilber FC; Bouvet M; Hiroshima Y; Chishima T; Matsuyama R; Singh SR; Endo I; Hoffman RM
Chemotherapy; 2018; 63(5):278-283. PubMed ID: 30673664
[TBL] [Abstract][Full Text] [Related]
11. Intra-arterial administration of tumor-targeting Salmonella typhimurium A1-R regresses a cisplatin-resistant relapsed osteosarcoma in a patient-derived orthotopic xenograft (PDOX) mouse model.
Igarashi K; Kawaguchi K; Murakami T; Kiyuna T; Miyake K; Nelson SD; Dry SM; Li Y; Yanagawa J; Russell TA; Singh AS; Yamamoto N; Hayashi K; Kimura H; Miwa S; Tsuchiya H; Eilber FC; Hoffman RM
Cell Cycle; 2017 Jun; 16(12):1164-1170. PubMed ID: 28494180
[TBL] [Abstract][Full Text] [Related]
12. Tumor-targeting Salmonella typhimurium A1-R overcomes nab-paclitaxel resistance in a cervical cancer PDOX mouse model.
Miyake K; Murata T; Murakami T; Zhao M; Kiyuna T; Kawaguchi K; Igarashi K; Miyake M; Lwin TM; Hozumi C; Komatsu S; Kikuchi T; Bouvet M; Shimoya K; Singh SR; Endo I; Hoffman RM
Arch Gynecol Obstet; 2019 Jun; 299(6):1683-1690. PubMed ID: 30953192
[TBL] [Abstract][Full Text] [Related]
13. A combination of irinotecan/cisplatinum and irinotecan/temozolomide or tumor-targeting Salmonella typhimurium A1-R arrest doxorubicin- and temozolomide-resistant myxofibrosarcoma in a PDOX mouse model.
Kiyuna T; Tome Y; Murakami T; Miyake K; Igarashi K; Kawaguchi K; Oshiro H; Higuchi T; Miyake M; Sugisawa N; Zhang Z; Razmjooei S; Wangsiricharoen S; Chmielowski B; Nelson SD; Russell TA; Dry SM; Li Y; Eckardt MA; Singh AS; Chawla S; Kanaya F; Eilber FC; Singh SR; Zhao M; Hoffman RM
Biochem Biophys Res Commun; 2018 Nov; 505(3):733-739. PubMed ID: 30292411
[TBL] [Abstract][Full Text] [Related]
14. Recombinant Methioninase Combined With Tumor-targeting
Igarashi K; Kawaguchi K; Zhao M; Han Q; Tan Y; Kiyuna T; Miyake K; Higuchi T; Nelson SD; Dry SM; Li Y; Yamamoto N; Hayashi K; Kimura H; Miwa S; Singh SR; Tsuchiya H; Hoffman RM
Anticancer Res; 2020 May; 40(5):2515-2523. PubMed ID: 32366396
[TBL] [Abstract][Full Text] [Related]
15. Efficacy of Tumor-Targeting Salmonella A1-R on a Melanoma Patient-Derived Orthotopic Xenograft (PDOX) Nude-Mouse Model.
Yamamoto M; Zhao M; Hiroshima Y; Zhang Y; Shurell E; Eilber FC; Bouvet M; Noda M; Hoffman RM
PLoS One; 2016; 11(8):e0160882. PubMed ID: 27500926
[TBL] [Abstract][Full Text] [Related]
16. High efficacy of tumor-targeting Salmonella typhimurium A1-R on a doxorubicin- and dactolisib-resistant follicular dendritic-cell sarcoma in a patient-derived orthotopic xenograft PDOX nude mouse model.
Kiyuna T; Murakami T; Tome Y; Kawaguchi K; Igarashi K; Zhang Y; Zhao M; Li Y; Bouvet M; Kanaya F; Singh A; Dry S; Eilber FC; Hoffman RM
Oncotarget; 2016 May; 7(22):33046-54. PubMed ID: 27105519
[TBL] [Abstract][Full Text] [Related]
17. Efficacy of Tumor-Targeting
Murakami T; Hiroshima Y; Miyake K; Kiyuna T; Endo I; Zhao M; Hoffman RM
Cells; 2019 Jun; 8(6):. PubMed ID: 31208120
[TBL] [Abstract][Full Text] [Related]
18. Tumor-targeting Salmonella typhimurium A1-R arrests a doxorubicin-resistant PDGFRA-amplified patient-derived orthotopic xenograft mouse model of pleomorphic liposarcoma.
Kiyuna T; Tome Y; Murakami T; Zhao M; Miyake K; Igarashi K; Kawaguchi K; Miyake M; Oshiro H; Higuchi T; Li Y; Dry SM; Nelson SD; Russell TA; Eckardt MA; Singh AS; Kanaya F; Eilber FC; Hoffman RM
J Cell Biochem; 2018 Sep; 119(9):7827-7833. PubMed ID: 29932244
[TBL] [Abstract][Full Text] [Related]
19.
Hamada K; Aoki Y; Yamamoto J; Hozumi C; Zhao M; Murata T; Sugisawa N; Bouvet M; Tsunoda T; Hoffman RM
In Vivo; 2021; 35(6):3067-3071. PubMed ID: 34697138
[TBL] [Abstract][Full Text] [Related]
20. Temozolomide regresses a doxorubicin-resistant undifferentiated spindle-cell sarcoma patient-derived orthotopic xenograft (PDOX): precision-oncology nude-mouse model matching the patient with effective therapy.
Igarashi K; Kawaguchi K; Kiyuna T; Miyake K; Miyake M; Li Y; Nelson SD; Dry SM; Singh AS; Elliott IA; Russell TA; Eckardt MA; Yamamoto N; Hayashi K; Kimura H; Miwa S; Tsuchiya H; Eilber FC; Hoffman RM
J Cell Biochem; 2018 Aug; 119(8):6598-6603. PubMed ID: 29737543
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]